GlassScriptPhysician profile
Ian T Watson
NPI 1689134900
$4,060.43
in general payments reported to CMS, 2019-2025
25 companies · $958 in 2025
The $958 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $241 · 2022: $894 · 2023: $1,065 · 2024: $902 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,371 · Education: $304 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,371.46 |
| Education | $303.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,229.47 | 2021-2025 | Rinvoq |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $516.25 | 2023-2025 | Siliq, Jublia, Arazlo |
| Regeneron Healthcare Solutions, INC. | $376.09 | 2021-2024 | Dupixent |
| Genzyme Corporation | $371.72 | 2022-2025 | |
| Janssen Biotech, INC. | $270.45 | 2023-2024 | Tremfya |
| Amgen INC. | $193.97 | 2021-2025 | Otezla, Otezla |
| Organon LLC | $179.70 | 2025 | |
| Galderma Laboratories, L.P. | $144.82 | 2022 | |
| Janssen Scientific Affairs, LLC | $127.32 | 2024 | Tremfya |
| Leo Pharma INC. | $115.21 | 2023-2025 | Adbry |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $66.79 | 2023 | Sotyktu |
| Lilly USA, LLC | $53.77 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Helsinn Therapeutics (U.S.), INC. | $53.05 | 2022-2023 | Valchlor |
| Incyte Corporation | $41.71 | 2024-2025 | Opzelura |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.87 | 2023 | Spevigo |
| Ucb, INC. | $32.74 | 2022-2023 | Cimzia |
| Genentech USA, INC. | $24.83 | 2022 | |
| Kyowa Kirin, INC. | $21.84 | 2022 | |
| Almirall LLC | $21.60 | 2025 | Klisyri |
| Sun Pharmaceutical Industries INC. | $18.37 | 2022 | |
| Exact Sciences Corporation | $16.99 | 2025 | The Cologuard Plus Collection Kit |
| Verrica Pharmaceuticals INC. | $16.42 | 2025 | Ycanth |
| Paratek Pharmaceuticals, INC. | $15.05 | 2024 | Nuzyra |
| Pfizer INC. | $13.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.